N/A
Completed N=102
Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors
Congenital Bleeding Disorder · Haemophilia A With Inhibitors · Haemophilia B With Inhibitors
Source: ClinicalTrials.gov NCT00703911 ↗
Enrolled (actual)
102
Serious AEs
0.0%
Results posted
Dec 2011
Primary outcomePrimary: Percentage of Bleed Treatments Resulting in Effective Bleed Resolution (All Bleed Episodes) — 61.7; 67.9; 62.2; 56.9 percentage of bleed episodes
Summary
This study was conducted in Africa, Europe, the Middle-East and South America. The primary objective of this registry was to observe the use of single dose and multi-dose use of activated recombinant human factor VII and to compare short-term outcomes, including effectiveness, safety, quality of life and treatment satisfaction with the approved treatments.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Bleed Treatments Resulting in Effective Bleed Resolution (All Bleed Episodes) |
61.7; 67.9; 62.2; 56.9 | — |
| PRIMARY Percentage of Bleed Treatments Resulting in Effective Bleed Resolution (Spontaneous Bleed Episodes) |
59.0; 62.6; 60.4; 55.7 | — |
| PRIMARY Percentage of Bleed Treatments Resulting in Effective Pain Relief (All Bleed Episodes) |
71.3; 82.1; 60.6; 69.7 | — |
| PRIMARY Percentage of Bleed Treatments Resulting in Effective Pain Relief (Spontaneous Bleed Episodes) |
68.0; 79.1; 58.2; 67.1 | — |
| SECONDARY Percentage of Bleed Treatments Resulting in Effective Haemostasis (Cessation of Bleeds) by Time Point (All Bleed Episodes) |
21.1; 16.8; 25.8; 21.5; 36.9; 32.5 | — |
| SECONDARY Percentage of Bleed Treatments Resulting in Effective Haemostasis (Cessation of Bleeds) by Time Point (Spontaneous Bleed Episodes) |
19.3; 7.7; 24.4; 23.6; 36.9; 27.8 | — |
| SECONDARY Percentage of Bleed Treatments Resulting in Effective Pain Relief by Time Point (All Bleed Episodes) |
27.7; 29.9; 19.8; 30.8; 53.1; 59.7 | — |
| SECONDARY Percentage of Bleed Treatments Resulting in Effective Pain Relief by Time Point (Spontaneous Bleed Episodes) |
24.7; 24.4; 18.7; 28.8; 49.1; 55.6 | — |
| SECONDARY Total Number of Injections (All Bleed Episodes) |
2; 2; 2; 1 | — |
| SECONDARY Total Number of Injections (Spontaneous Bleed Episodes) |
2; 2; 2; 1 | — |
| SECONDARY Total Exposure (Cumulative Dose) to Activated Recombinant Human Factor VII (All Bleed Episodes) |
270; 267; 256; 270 | — |
| SECONDARY Total Exposure (Cumulative Dose) to Activated Recombinant Human Factor VII (Spontaneous Bleed Episodes) |
184; 284; 270; 270 | — |
| SECONDARY Percentage of Patients Reporting Satisfaction With Symptom Relief (All Bleed Episodes) |
72.7; 82.1; 69.3; 67.8 | — |
| SECONDARY Percentage of Bleed Treatments Resulting in Patient Satisfaction With Symptom Relief (Spontaneous Bleed Episodes) |
68.2; 75.0; 69.2; 63.1 | — |
| SECONDARY Percentage of Bleed Treatments Resulting in Patient Satisfaction With Ease of Use (All Bleed Episodes) |
74.9; 84.6; 74.8; 67.8 | — |
| SECONDARY Percentage of Bleed Treatments Resulting in Patient Satisfaction With Ease of Use (Spontaneous Bleed Episodes) |
69.1; 81.5; 69.2; 61.0 | — |
| SECONDARY Overall Time to Cessation of Bleed/Achievement of Haemostasis (All Bleed Episodes) |
1200; 720; NA; 1200 | — |
| SECONDARY Overall Time to Cessation of Bleed/Achievement of Haemostasis (Spontaneous Bleed Episodes) |
1200; 600; NA; 1200 | — |
| SECONDARY Overall Time to Cessation/Achievement of Haemostasis (Spontaneous Bleed Episodes) |
600; 600; NA; 480 | — |
| SECONDARY Childrens' Health Related Quality of Life (Haemo-QoL): Overall Score |
47.49; 54.12 | — |
| SECONDARY Adults' Health Related Quality of Life (Haemo-QoL-A): Overall Score |
35.31; 34.46 | — |
Eligibility Criteria
Inclusion Criteria
- Diagnosed with haemophilia A or B with inhibitors
- Experience mild to moderate spontaneous bleeds which require on-demand treatment and who are currently prescribed activated recombinant human factor VII
- Be able and willing to provide informed consent (or proxy consent by caregiver, if applicable), as required by local research ethics committee, governmental or regulatory authorities
- Be willing to provide information on at least one alternate contact person in the event that the patient be somehow lost-to-follow-up over the course of registry participation (not applicable if patient is withdrawn)
Exclusion Criteria
- Known hypersensitivity to the active substance or the excipients in the formulation of activated recombinant human factor VII, or to mouse, hamster or bovine protein
Data sourced from ClinicalTrials.gov (NCT00703911). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.